Exagen Diagnostics has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO). No terms were given in the filing. The company plans to file on the Nasdaq Global Market under the symbol EXDX.
The underwriters for the offering are Leerink Partners, William Blair and Baird.
This is a commercial-stage diagnostics company that is committed to addressing the significant unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases (ARD). These chronic diseases can cause lifelong inflammation in the joints, tissues and internal organs, resulting in serious complications, such as irreversible organ damage. The accurate, timely and differential diagnosis for patients suffering from the approximately 30 ARDs is critical as treatment for each disease can vary, and inappropriate or delayed therapy may expose patients to unnecessary risks or the hazards of uncontrolled disease activity. Physicians face significant difficulties in making a definitive diagnosis of a specific ARD because patients with different diseases often present with a common set of symptoms.
Exagen currently markets five products under its Avise brand to provide an accurate, timely and differential diagnosis and to optimize the treatment of ARDs. The company processed roughly 9,300 patient specimens for its lead diagnostic product line, Avise SLE, in 2013, about 27,900 in 2014 and around 17,900 in the first six months of 2015.
The diagnosis and treatment of ARDs is generally provided by the community rheumatologist, a sub-specialty of internal medicine that includes approximately 3,500 physicians in the United States.
The company plans to use the proceeds from this offering ultimately to support its operations. Exagen will set aside some of the proceeds for selling and marketing, research and development and capital expenditures, and the remainder for working capital and general corporate purposes.
ALSO READ: 4 Jefferies Top Value Stock Picks to Buy Now
Is Your Money Earning the Best Possible Rate? (Sponsor)
Let’s face it: If your money is just sitting in a checking account, you’re losing value every single day. With most checking accounts offering little to no interest, the cash you worked so hard to save is gradually being eroded by inflation.
However, by moving that money into a high-yield savings account, you can put your cash to work, growing steadily with little to no effort on your part. In just a few clicks, you can set up a high-yield savings account and start earning interest immediately.
There are plenty of reputable banks and online platforms that offer competitive rates, and many of them come with zero fees and no minimum balance requirements. Click here to see if you’re earning the best possible rate on your money!
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
